Functional analysis and in vitro correction of splicing FAH mutations causing tyrosinemia type I

Area of Science:

• Molecular Biology
• Genetics
• Biochemistry

Background:

• Hereditary tyrosinemia type I (HT1) results from fumarylacetoacetate hydrolase (FAH) deficiency, leading to toxic metabolite accumulation and liver damage.
• Splicing mutations in the FAH gene can cause HT1 by disrupting normal RNA processing.

Purpose of the Study:

• To characterize four splicing mutations in the FAH gene identified in HT1 patients.
• To investigate the functional impact of these mutations on FAH gene splicing.
• To explore potential therapeutic strategies using splicing-modulating compounds and SR proteins.

Main Methods:

• Minigene assays were used to analyze the splicing effects of four FAH gene mutations (c.82-1G>A, c.913G>C, c.836A>G, c.1062+5G>A).
• The impact of splicing modulators (valproic acid, phenyl butyrate, etc.) and SR protein overexpression on mutant minigenes was assessed.
• Transcriptional profiles of mutant minigenes were analyzed.

Main Results:

• All four FAH mutations were confirmed to affect splicing, causing exon skipping or cryptic splice site activation.
• A partial restoration of correctly spliced transcripts was observed for the c.836A>G mutation.
• Splicing modulators and SR protein overexpression were tested for their effects on mutant transcripts.

Conclusions:

• Functional studies are crucial for understanding mutations that affect splicing processes.
• The findings suggest potential therapeutic avenues for HT1 and other diseases caused by splicing defects.